Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.42 USD | +8.40% | +9.23% | +40.59% |
03-04 | Passage Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
03-04 | Passage Bio, Inc. Appoints Kathleen Borthwick as Chief Financial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.59% | 80.71M | |
+8.96% | 105B | |
-0.51% | 104B | |
+5.79% | 22.94B | |
-12.74% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-8.78% | 16.96B | |
+8.27% | 14.16B | |
+39.74% | 12.63B |
- Stock Market
- Equities
- PASG Stock
- News Passage Bio, Inc.
- Passage Bio Says Independent Panel OKs Two More Planned Cohorts in Trial of PBGM01 in GM1 Gangliosidosis